FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1505136191> ?p ?o ?g. }

• W1505136191 abstract "Background Antibiotics are widely prescribed; however they can cause disturbances in gastrointestinal flora which may lead to reduced resistance to pathogens such as Clostridium difficile (C. difficile). Probiotics are live organisms thought to balance the gastrointestinal flora. Objectives The primary objectives were to assess the efficacy and safety of probiotics for preventing Clostridium difficile‐associated diarrhea (CDAD) or C. difficile infection in adults and children. Search methods On February 21, 2013 we searched PubMed (1966‐2013), EMBASE (1966‐2013), Cochrane Central Register of Controlled Trials (The Cochrane Library 2013, Issue 1), CINAHL (1982‐2013), AMED (1985‐2013), and ISI Web of Science. Additionally, we conducted an extensive grey literature search including contact with industry representatives. Selection criteria Randomized controlled (placebo, alternative prophylaxis, or no treatment control) trials investigating probiotics (any strain, any dose) for prevention of CDAD, or C. difficile infection were considered for inclusion. Data collection and analysis Two authors independently and in duplicate extracted data and assessed risk of bias using pre‐constructed, and piloted, data extraction forms. Any disagreements were resolved by a third adjudicator. For articles published in abstract form only, further information was sought by contacting principal authors. The primary outcome was the incidence of CDAD. Secondary outcomes included the incidence of C. difficile infection, adverse events, antibiotic‐associated diarrhea (AAD) and length of hospital stay. Dichotomous outcomes (e.g. incidence of CDAD) were pooled using a random‐effects model to calculate the relative risk and corresponding 95% confidence interval (95% CI). Continuous outcomes (e.g. length of hospital) were pooled using a random‐effects model to calculate the mean difference and corresponding 95% CI. Sensitivity analyses were conducted to explore the impact of missing data on efficacy and safety outcomes. For the sensitivity analyses, we assumed that the event rate for those participants in the control group who had missing data was the same as the event rate for those participants in the control group who were successfully followed. For the probiotic group we calculated effects using the following assumed ratios of event rates in those with missing data in comparison to those successfully followed: 1.5:1, 2:1, 3:1, and 5:1. To explore possible explanations for heterogeneity, a priori subgroup analysis were conducted on probiotic species, dose, adult versus pediatric population, and risk of bias.The overall quality of the evidence supporting each outcome was assessed using the GRADE criteria. Main results A total of 1871 studies were identified with 31 (4492 participants) meeting eligibility requirements for our review. Overall 11 studies were rated as a high risk of bias due mostly to missing outcome data. A complete case analysis (i.e. participants who completed the study) of those trials investigating CDAD (23 trials, 4213 participants) suggests that probiotics significantly reduce this risk by 64%. The incidence of CDAD was 2.0% in the probiotic group compared to 5.5% in the placebo or no treatment control group (RR 0.36; 95% CI 0.26 to 0.51). Sixteen of 23 trials had missing CDAD data ranging from 5% to 45%. These results proved robust to sensitivity analyses of plausible and worst‐plausible assumptions regarding missing outcome data and were similar whether considering trials in adults versus children, lower versus higher doses, different probiotic species, or higher versus lower risk of bias. Our judgment is that the overall evidence warrants moderate confidence in this large relative risk reduction. We downgraded the overall quality of evidence for CDAD to ‘moderate’ due to imprecision. There were few events (154) and the calculated optimal information size (n = 8218) was more than the total sample size. With respect to the incidence of C. difficile infection, a secondary outcome, pooled complete case results from 13 trials (961 participants) did not show a statistically significant reduction. The incidence of C. difficile infection was 12.6% in the probiotics group compared to 12.7% in the placebo or no treatment control group (RR 0.89; 95% CI 0.64 to 1.24). Adverse events were assessed in 26 studies (3964 participants) and our pooled complete case analysis indicates probiotics reduce the risk of adverse events by 20% (RR 0.80; 95% CI 0.68 to 0.95). In both treatment and control groups the most common adverse events included abdominal cramping, nausea, fever, soft stools, flatulence, and taste disturbance. For the short‐term use of probiotics in patients that are not immunocompromised or severely debilitated, we consider the strength of this evidence to be moderate. Authors' conclusions Based on this systematic review and meta‐analysis of 23 randomized controlled trials including 4213 patients, moderate quality evidence suggests that probiotics are both safe and effective for preventing Clostridium difficile‐associated diarrhea." @default.
• W1505136191 created "2016-06-24" @default.
• W1505136191 creator A5000473326 @default.
• W1505136191 creator A5009362952 @default.
• W1505136191 creator A5028677250 @default.
• W1505136191 creator A5029988883 @default.
• W1505136191 creator A5038110546 @default.
• W1505136191 creator A5054011306 @default.
• W1505136191 creator A5090043842 @default.
• W1505136191 date "2013-05-31" @default.
• W1505136191 modified "2023-10-09" @default.
• W1505136191 title "Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children" @default.
• W1505136191 cites W103084301 @default.
• W1505136191 cites W1496786341 @default.
• W1505136191 cites W1511524925 @default.
• W1505136191 cites W1679685070 @default.
• W1505136191 cites W1713250718 @default.
• W1505136191 cites W179907124 @default.
• W1505136191 cites W1925194624 @default.
• W1505136191 cites W1954829662 @default.
• W1505136191 cites W1965180855 @default.
• W1505136191 cites W1966875539 @default.
• W1505136191 cites W1967928126 @default.
• W1505136191 cites W1973743544 @default.
• W1505136191 cites W1973748105 @default.
• W1505136191 cites W1977529839 @default.
• W1505136191 cites W1980472079 @default.
• W1505136191 cites W1980621284 @default.
• W1505136191 cites W1984572269 @default.
• W1505136191 cites W1985338395 @default.
• W1505136191 cites W1986388387 @default.
• W1505136191 cites W1990395027 @default.
• W1505136191 cites W1994689525 @default.
• W1505136191 cites W1994890638 @default.
• W1505136191 cites W1995059496 @default.
• W1505136191 cites W1996054458 @default.
• W1505136191 cites W2000215297 @default.
• W1505136191 cites W2000364441 @default.
• W1505136191 cites W2002190089 @default.
• W1505136191 cites W2004330309 @default.
• W1505136191 cites W2005877606 @default.
• W1505136191 cites W2007010240 @default.
• W1505136191 cites W2007686582 @default.
• W1505136191 cites W2008087801 @default.
• W1505136191 cites W2013446759 @default.
• W1505136191 cites W2017293630 @default.
• W1505136191 cites W2018025826 @default.
• W1505136191 cites W2019240364 @default.
• W1505136191 cites W2019424331 @default.
• W1505136191 cites W2022119311 @default.
• W1505136191 cites W2024378781 @default.
• W1505136191 cites W2029125886 @default.
• W1505136191 cites W2029340717 @default.
• W1505136191 cites W2030171620 @default.
• W1505136191 cites W2030213770 @default.
• W1505136191 cites W2030409548 @default.
• W1505136191 cites W2035258340 @default.
• W1505136191 cites W2035547963 @default.
• W1505136191 cites W2036272323 @default.
• W1505136191 cites W2039418122 @default.
• W1505136191 cites W204046373 @default.
• W1505136191 cites W2043406878 @default.
• W1505136191 cites W2046776539 @default.
• W1505136191 cites W2048852765 @default.
• W1505136191 cites W2053254936 @default.
• W1505136191 cites W2054620165 @default.
• W1505136191 cites W2054664713 @default.
• W1505136191 cites W2057619726 @default.
• W1505136191 cites W2058317978 @default.
• W1505136191 cites W2059386369 @default.
• W1505136191 cites W2059825445 @default.
• W1505136191 cites W2060776197 @default.
• W1505136191 cites W2077666564 @default.
• W1505136191 cites W2077829950 @default.
• W1505136191 cites W2082697300 @default.
• W1505136191 cites W2083815143 @default.
• W1505136191 cites W2085950961 @default.
• W1505136191 cites W2086771104 @default.
• W1505136191 cites W2087617620 @default.
• W1505136191 cites W2087655186 @default.
• W1505136191 cites W2088092352 @default.
• W1505136191 cites W2091875959 @default.
• W1505136191 cites W2094759912 @default.
• W1505136191 cites W2096329679 @default.
• W1505136191 cites W2101645084 @default.
• W1505136191 cites W2103358806 @default.
• W1505136191 cites W2108349766 @default.
• W1505136191 cites W2110737901 @default.
• W1505136191 cites W2118266802 @default.
• W1505136191 cites W2118299459 @default.
• W1505136191 cites W2119529742 @default.
• W1505136191 cites W2119605658 @default.
• W1505136191 cites W2120773585 @default.
• W1505136191 cites W2121291178 @default.
• W1505136191 cites W2121691965 @default.
• W1505136191 cites W2124079555 @default.
• W1505136191 cites W2125435699 @default.
• W1505136191 cites W2127805721 @default.
• W1505136191 cites W2139168999 @default.
• W1505136191 cites W2139895568 @default.

• next